Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $11.00. They now have an "overweight" rating on the stock.
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at HC Wainwright from $16.00 to $20.00. They now have a "buy" rating on the stock.
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $16.00 price target on the stock.